CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer

被引:18
作者
Ma, Zhe [1 ]
Chao, Fan [1 ]
Wang, Shiyu [1 ]
Song, Zhenyu [1 ]
Zhuo, Zhiyuan [1 ]
Zhang, Jinguo [2 ]
Xu, Guoxiong [2 ]
Chen, Gang [1 ]
机构
[1] Fudan Univ, Jinshan Hosp, Dept Urol, 1508 Longhang Rd, Shanghai 201508, Peoples R China
[2] Fudan Univ, Jinshan Hosp, Res Ctr Clin Res, Shanghai 201508, Peoples R China
基金
上海市自然科学基金;
关键词
CTHRC1; microRNA-30e-5p; Oncogenic gene; Prostate cancer; TRIPLE-HELIX REPEAT; EXPRESSION; PROGRESSION; MECHANISMS; MICRORNAS; PROGNOSIS; THERAPY;
D O I
10.1016/j.bbrc.2020.02.098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Collagen Triple Helix Repeat Containing 1 (CTHRC1) has been picked out as a cancer-related, secreted glycoprotein that possesses multifaceted functions such as wound repair, the formation of adipose tissue, hepatocytes fibrosis, and bone remodeling. This study aims to explore the biological function and the profound regulative mechanism of CTHRC1 in human prostate cancer (PCa). We found that CTHRC1 was upregulated in patients with PCa. The knockdown of CTHRC1 suppressed PCa cell proliferation, invasion, migration, and colony formation significantly. The expression of CTHRC1 was down-regulated and up-regulated by miR-30e-5p mimics and inhibitors, respectively, in PCa cells. The dual-luciferase reporter assay validated the binding of miR-30e-5p with CTHRC1 mRNA, indicating the regulation of CTHC1 by miR-30e-5p. In consequence, this study demonstrated that CTHRC1 acts as an oncogenic gene and targeting the miR-30e-5p-CTHRC1 axis may provide novel therapeutic treatment for PCa. (C) 2020 The Authors. Published by Elsevier Inc.
引用
收藏
页码:418 / 424
页数:7
相关论文
共 35 条
[1]   Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease [J].
Bian, Zhaolian ;
Miao, Qi ;
Zhong, Wei ;
Zhang, Haiyan ;
Wang, Qixia ;
Peng, Yanshen ;
Chen, Xiaoyu ;
Guo, Canjie ;
Shen, Li ;
Yang, Fan ;
Xu, Jie ;
Qiu, Dekai ;
Fang, Jingyuan ;
Friedman, Scott ;
Tang, Ruqi ;
Gershwin, M. Eric ;
Ma, Xiong .
JOURNAL OF AUTOIMMUNITY, 2015, 63 :76-87
[2]  
Bregni G, 2018, NEW ENGL J MED, V379, P1380, DOI 10.1056/NEJMc1810065
[3]  
Chen SL, 2017, SCI REP-UK, V7, DOI [10.1038/srep40003, 10.1038/s41598-017-12388-2]
[4]   Overexpression of CTHRC1 in Hepatocellular Carcinoma Promotes Tumor Invasion and Predicts Poor Prognosis [J].
Chen, Yu-Ling ;
Wang, Ting-Huang ;
Hsu, Hey-Chi ;
Yuan, Ray-Hwang ;
Jeng, Yung-Ming .
PLOS ONE, 2013, 8 (07)
[5]   Immune mediators in the tumor microenvironment of prostate cancer [J].
Dai, Jinlu ;
Lu, Yi ;
Roca, Hernan ;
Keller, Jill M. ;
Zhang, Jian ;
McCauley, Laurie K. ;
Keller, Evan T. .
CHINESE JOURNAL OF CANCER, 2017, 36
[6]   Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy [J].
de la Taille, Alexandre ;
Martinez-Pineiro, Luis ;
Cabri, Patrick ;
Houchard, Aude ;
Schalken, Jack .
BJU INTERNATIONAL, 2017, 119 (01) :74-81
[7]   Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context [J].
Draisma, Gerrit ;
Etzioni, Ruth ;
Tsodikov, Alex ;
Mariotto, Angela ;
Wever, Elisabeth ;
Gulati, Roman ;
Feuer, Eric ;
de Koning, Harry .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (06) :374-383
[8]   Epithelial-mesenchymal transition and the invasive potential of tumors [J].
Gavert, Nancy ;
Ben-Ze'ev, Avri .
TRENDS IN MOLECULAR MEDICINE, 2008, 14 (05) :199-209
[9]   Screening for Prostate Cancer With the Prostate-Specific Antigen Test A Review of Current Evidence [J].
Hayes, Julia H. ;
Barry, Michael J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (11) :1143-1149
[10]   High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis [J].
Hou, Minzhi ;
Cheng, Zhiqiang ;
Shen, Hongwei ;
He, Shanyang ;
Li, Yang ;
Pan, Yunping ;
Feng, Chongjin ;
Chen, Xinlin ;
Zhang, Yang ;
Lin, Millicent ;
Wang, Liantang ;
Ke, Zunfu .
ONCOTARGET, 2015, 6 (34) :35813-35829